Compare ATHM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | IMNM |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2013 | 2020 |
| Metric | ATHM | IMNM |
|---|---|---|
| Price | $19.30 | $21.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $28.00 | ★ $32.80 |
| AVG Volume (30 Days) | 577.8K | ★ 931.8K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 9.11% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $5.67 | $18.41 |
| Revenue Next Year | $2.17 | $863.23 |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.87 | $5.15 |
| 52 Week High | $30.19 | $27.65 |
| Indicator | ATHM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 45.76 |
| Support Level | N/A | $18.98 |
| Resistance Level | $23.96 | $22.57 |
| Average True Range (ATR) | 0.68 | 1.07 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 41.02 | 51.38 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider with 30% market share, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.